|
|
Issue 21, 2010
HOT TOPICS IN CARDIOLOGY
n-3 Polyunsaturated fatty acids and cardiovascular disease in patients with chronic kidney disease: focus on lipids and lipoproteins
| Publ. date: | 2010 |
| ISBN: | 978-88-6450-065-2 |
| ISSN: | 1973-9621 |
| E-ISSN: | 2036-0924 |
| DOI: | 10.4147/HTC-102100 |
Abstract
Cardiovascular disease (CVD) is the main cause of increased mortality in patients with chronic kidney disease (CKD). Patients with CKD have an accumulation of risk factors for CVD, including mixed dyslipidemia, specific for the uremic state. Randomized controlled trials (RCTs) in patients with CKD are limited, and existing RCTs with statins have been disappointingly negative. Both epidemiological and interventional data support a cardioprotective effect from dietary intake of fatty fish or supplementation with n-3 fatty acids. Several mechanisms may explain why n-3 fatty acids have a beneficial effect on patients with CVD, and the effects on lipids and triglycerides are especially well described. In patients with CKD, the effect of n-3 fatty acids has not been extensively studied. This review will provide an update on existing data concerning treatment with n-3 fatty acids in patients with CKD, with a special focus on lipids and lipoproteins.
Table of contents
Foreword
This issue of Hot Topics in Cardiology is a mixture of 2 hot topics and how they interact. One key area in cardiology focuses on high-risk patients. Recently, a vital connection has been found between cardiovascular disease (CVD) and chronic kidney disease (CKD), based on estimated glomerular filtration rate. Patients with both these designations are considered high-risk patients. This is somewhat akin to patients with diabetes mellitus, whom we all know are high risk. Now that we can easily identify patients with CKD and CVD, and label them, we can focus our attention on how to improve their care. This is all the more important because they are increasing in numbers in our daily practice. The other hot area in cardiology focuses on the benefits of omega-3 fatty acids. This is a simple and safe treatment that has proved to be quite effective for prevention of CVD. Studies such as the Japan EPA Lipid Intervention Study (JELIS) and the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico (GISSI) Prevenzione trial have shown reductions in major cardiovascular events, including mortality, with use of omega-3 fatty acids. In this issue, Svensson and Christensen present these two hot topics, and the many advances and improvements in care of patients with CKD when using omega-3 fatty acids. Thus, readers will learn a great deal on the benefits of omega-3 fatty acids and how they can improve the care of patients with CVD and CKD.
ARTICLES
n-3 Polyunsaturated fatty acids and cardiovascular disease in patients with chronic kidney disease: focus on lipids and lipoproteins
Jeppe H. Christensen, My Svensson
If you have a Username and Password, you may already access to this article. Please login below.
If you do not have a Username and Password, click the "Register" button below to purchase this article.
|
 |
|
 |
| |
Editors-in-chief
Christopher P. Cannon - MD Sergio Dalla Volta - MD, PhD
While cardiology over the last 15 years has progressed to a great extent in various aspects, it has not progressed in a harmonious manner. Advances in biophysics, molecular biology, genetics, and, les...
Past editor-in-chief
Philip A. Poole-Wilson - MD, FRCP, FACC, FESC, FMedSci
|
|
|
|
|
|
| |
|
|
|